The Association between Metformin and Survival of Head and Neck Cancer: A Systematic Review and Meta-Analysis of 7 Retrospective Cohort Studies

Author(s): Yongbo Wang, Tao Fu, Yu Liu, Guifang Yang, Chuanhua Yu, Zhi-Jiang Zhang*

Journal Name: Current Pharmaceutical Design

Volume 26 , Issue 26 , 2020


Become EABM
Become Reviewer
Call for Editor

Abstract:

Background: Metformin has been associated with improved survival outcomes in various malignancies. However, observational studies in head and neck cancer are inconsistent.

Objective: The study aimed to summarize and quantify the relationship between metformin use and the survival of head and neck cancer.

Methods: A meta-analysis based on cohort studies was systematically conducted (published up to Jan 18, 2020), identified from PubMed, Embase, Web of Science, Cochrane Library, Google Scholar, and Scopus databases. Summary hazard ratios (HR) and 95% confidence intervals (CI) were calculated using a random-effects model.

Results: Seven retrospective cohort studies including 3,285 head and neck cancer patients were included. The association between the use of metformin and cancer survival was not statistically significant: summarized HR of 0.89 (95% CI 0.66-1.18, P=0.413, I2=64.0%) for overall survival, summarized HR of 0.65 (95% CI 0.31-1.35, P=0.246, I2=60.3%) for disease-free survival, and summarized HR of 0.69 (95% CI 0.40-1.20, P=0.191, I2=73.1%) for disease-specific survival.

Conclusion: In this meta-analysis of 7 retrospective cohort studies, there was not a statistically significant association between the use of metformin and better survival for head and neck cancer. However, the analysis may have been underpowered. More studies of prospective designs with larger sample sizes are needed to investigate the effect of metformin on the survival of head and neck cancer.

Keywords: Metformin, head and neck cancer, overall survival, diabetes mellitus, immortal time bias, prospective designs.

[1]
Pezzuto F, Buonaguro L, Caponigro F, et al. Update on head and neck cancer: current knowledge on epidemiology, risk factors, molecular features and novel therapies. Oncology 2015; 89(3): 125-36.
[http://dx.doi.org/10.1159/000381717] [PMID: 25967534]
[2]
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86.
[http://dx.doi.org/10.1002/ijc.29210] [PMID: 25220842]
[3]
Gao J, Panizza B, Johnson NW, Coman S, Clough AR. Basic consideration of research strategies for head and neck cancer. Front Med 2012; 6(4): 339-53.
[http://dx.doi.org/10.1007/s11684-012-0213-7] [PMID: 23054500]
[4]
Zhang ZJ, Hao K, Shi R, et al. Glutathione S-transferase M1 (GSTM1) and glutathione S-transferase T1 (GSTT1) null polymorphisms, smoking, and their interaction in oral cancer: a HuGE review and meta-analysis. Am J Epidemiol 2011; 173(8): 847-57.
[http://dx.doi.org/10.1093/aje/kwq480] [PMID: 21436184]
[5]
Hashibe M, Brennan P, Chuang SC, et al. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev 2009; 18(2): 541-50.
[http://dx.doi.org/10.1158/1055-9965.EPI-08-0347] [PMID: 19190158]
[6]
Zeng J, Tang Y, Wu P, et al. Alcohol consumption, tobacco smoking, betel quid chewing and oral health associations with hypopharyngeal cancer among men in Central South China: a case-control study. Cancer Manag Res 2019; 11: 6353-64.
[http://dx.doi.org/10.2147/CMAR.S203439] [PMID: 31372040]
[7]
Zhang ZJ. The association between type 2 diabetes and head and neck squamous cell carcinoma. Cancer Epidemiol 2014; 38(2): 209.
[http://dx.doi.org/10.1016/j.canep.2014.02.008] [PMID: 24631418]
[8]
Stott-Miller M, Chen C, Chuang SC, et al. History of diabetes and risk of head and neck cancer: a pooled analysis from the international head and neck cancer epidemiology consortium. Cancer Epidemiol Biomarkers Prev 2012; 21(2): 294-304.
[http://dx.doi.org/10.1158/1055-9965.EPI-11-0590] [PMID: 22144496]
[9]
Sanchez-Rangel E, Inzucchi SE. Metformin: clinical use in type 2 diabetes. Diabetologia 2017; 60(9): 1586-93.
[http://dx.doi.org/10.1007/s00125-017-4336-x] [PMID: 28770321]
[10]
Zhang ZJ, Li S. The prognostic value of metformin for cancer patients with concurrent diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 2014; 16(8): 707-10.
[http://dx.doi.org/10.1111/dom.12267] [PMID: 24460896]
[11]
Yin M, Zhou J, Gorak EJ, Quddus F. Metformin is associated with survival benefit in cancer patients with concurrent type 2 diabetes: a systematic review and meta-analysis. Oncologist 2013; 18(12): 1248-55.
[http://dx.doi.org/10.1634/theoncologist.2013-0111] [PMID: 24258613]
[12]
Zhang ZJ, Yuan J, Bi Y, Wang C, Liu Y. The effect of metformin on biomarkers and survivals for breast cancer- a systematic review and meta-analysis of randomized clinical trials. Pharmacol Res 2019; 141: 551-5.
[http://dx.doi.org/10.1016/j.phrs.2019.01.036] [PMID: 30664988]
[13]
Marrone KA, Zhou X, Forde PM, et al. A randomized phase II study of metformin plus paclitaxel/carboplatin/bevacizumab in patients with chemotherapy-naïve advanced or metastatic nonsquamous non-small cell lung cancer. Oncologist 2018; 23(7): 859-65.
[http://dx.doi.org/10.1634/theoncologist.2017-0465] [PMID: 29487223]
[14]
Farmer RE, Ford D, Forbes HJ, et al. Metformin and cancer in type 2 diabetes: a systematic review and comprehensive bias evaluation. Int J Epidemiol 2017; 46(2): 728-44.
[http://dx.doi.org/10.1093/ije/dyx046] [PMID: 28031313]
[15]
Wei M, Liu Y, Bi Y, Zhang ZJ. Metformin and pancreatic cancer survival: Real effect or immortal time bias? Int J Cancer 2019; 145(7): 1822-8.
[http://dx.doi.org/10.1002/ijc.32254] [PMID: 30848544]
[16]
Lee DJ, McMullen CP, Foreman A, et al. Impact of metformin on disease control and survival in patients with head and neck cancer: a retrospective cohort study. J Otolaryngol Head Neck Surg 2019; 48(1): 34.
[http://dx.doi.org/10.1186/s40463-019-0348-5] [PMID: 31345259]
[17]
Alcusky M, Keith SW, Karagiannis T, Rabinowitz C, Louis DZ, Maio V. Metformin exposure and survival in head and neck cancer: A large population-based cohort study. J Clin Pharm Ther 2019; 44(4): 588-94.
[http://dx.doi.org/10.1111/jcpt.12820] [PMID: 31293011]
[18]
Stokes WA, Eguchi M, Amini A, et al. Survival impact and toxicity of metformin in head and neck cancer: An analysis of the SEER-Medicare dataset. Oral Oncol 2018; 84: 12-9.
[http://dx.doi.org/10.1016/j.oraloncology.2018.06.022] [PMID: 30115470]
[19]
Quimby AE, Lebo NL, Griffiths R, Hall S, Dimitroulakos J, Johnson-Obaseki S. Does metformin usage improve survival in head and neck squamous cell carcinoma? A population-based study. J Otolaryngol Head Neck Surg 2018; 47(1): 74.
[http://dx.doi.org/10.1186/s40463-018-0322-7] [PMID: 30514404]
[20]
Kwon M, Roh JL, Song J, et al. Effect of metformin on progression of head and neck cancers, occurrence of second primary cancers, and cause-specific survival. Oncologist 2015; 20(5): 546-53.
[http://dx.doi.org/10.1634/theoncologist.2014-0426] [PMID: 25802404]
[21]
Sandulache VC, Hamblin JS, Skinner HD, Kubik MW, Myers JN, Zevallos JP. Association between metformin use and improved survival in patients with laryngeal squamous cell carcinoma. Head Neck 2014; 36(7): 1039-43.
[http://dx.doi.org/10.1002/hed.23409] [PMID: 23784886]
[22]
Tsou YA, Chang WD, Lu JJ, et al. The effect of metformin use on hypopharyngeal squamous cell carcinoma in diabetes mellitus patients. BMC Cancer 2019; 19(1): 862.
[http://dx.doi.org/10.1186/s12885-019-6083-5] [PMID: 31470817]
[23]
Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009; 339: b2535.
[http://dx.doi.org/10.1136/bmj.b2535] [PMID: 19622551]
[24]
Wei M, Liu Y, Wang C, et al. The need for differentiating diabetes-specific mortality from total mortality when comparing metformin with insulin regarding cancer survival. Acta Diabetol 2017; 54(2): 219-20.
[http://dx.doi.org/10.1007/s00592-016-0933-2] [PMID: 27796654]
[25]
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 2010; 25(9): 603-5.
[http://dx.doi.org/10.1007/s10654-010-9491-z] [PMID: 20652370]
[26]
Higgins JPT, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med 2002; 21(11): 1539-58.
[http://dx.doi.org/10.1002/sim.1186] [PMID: 12111919]
[27]
Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997; 315(7109): 629-34.
[http://dx.doi.org/10.1136/bmj.315.7109.629] [PMID: 9310563]
[28]
Saka Herrán C, Jané-Salas E, Estrugo Devesa A, López-López J. Protective effects of metformin, statins and anti-inflammatory drugs on head and neck cancer: A systematic review. Oral Oncol 2018; 85: 68-81.
[http://dx.doi.org/10.1016/j.oraloncology.2018.08.015] [PMID: 30220322]
[29]
Rêgo DF, Pavan LM, Elias ST, De Luca Canto G, Guerra EN. Effects of metformin on head and neck cancer: a systematic review. Oral Oncol 2015; 51(5): 416-22.
[http://dx.doi.org/10.1016/j.oraloncology.2015.01.007] [PMID: 25636350]
[30]
Zhang ZJ. Metformin and reduced risk of cancer in the Hong Kong Diabetes Registry: real effect or immortal time bias? J Gen Intern Med 2019; 34(7): 1154-7.
[http://dx.doi.org/10.1007/s11606-019-04982-z] [PMID: 31025306]
[31]
Zhang ZJ, Bi Y, Li S, et al. Reduced risk of lung cancer with metformin therapy in diabetic patients: a systematic review and meta-analysis. Am J Epidemiol 2014; 180(1): 11-4.
[http://dx.doi.org/10.1093/aje/kwu124] [PMID: 24920786]
[32]
Zhang ZJ, Zheng ZJ, Kan H, et al. Reduced risk of colorectal cancer with metformin therapy in patients with type 2 diabetes: a meta-analysis. Diabetes Care 2011; 34(10): 2323-8.
[http://dx.doi.org/10.2337/dc11-0512] [PMID: 21949223]
[33]
Zhang ZJ, Zheng ZJ, Shi R, Su Q, Jiang Q, Kip KE. Metformin for liver cancer prevention in patients with type 2 diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab 2012; 97(7): 2347-53.
[http://dx.doi.org/10.1210/jc.2012-1267] [PMID: 22523334]
[34]
Kheirandish M, Mahboobi H, Yazdanparast M, Kamal W, Kamal MA. Anti-cancer effects of metformin: recent evidences for its role in prevention and treatment of cancer. Curr Drug Metab 2018; 19(9): 793-7.
[http://dx.doi.org/10.2174/1389200219666180416161846] [PMID: 29663879]
[35]
Harada K, Ferdous T, Harada T, Ueyama Y. Metformin in combination with 5-fluorouracil suppresses tumor growth by inhibiting the Warburg effect in human oral squamous cell carcinoma. Int J Oncol 2016; 49(1): 276-84.
[http://dx.doi.org/10.3892/ijo.2016.3523] [PMID: 27210058]
[36]
Faubert B, Boily G, Izreig S, et al. AMPK is a negative regulator of the Warburg effect and suppresses tumor growth in vivo. Cell Metab 2013; 17(1): 113-24.
[http://dx.doi.org/10.1016/j.cmet.2012.12.001] [PMID: 23274086]
[37]
Mallik R, Chowdhury TA. Metformin in cancer. Diabetes Res Clin Pract 2018; 143: 409-19.
[http://dx.doi.org/10.1016/j.diabres.2018.05.023] [PMID: 29807101]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 26
ISSUE: 26
Year: 2020
Published on: 11 August, 2020
Page: [3161 - 3170]
Pages: 10
DOI: 10.2174/1381612826666200218095310
Price: $65

Article Metrics

PDF: 21
HTML: 2